reception@mymindmedicine.com.au
+61 7 3040 8208 

Innovations in Mental Health Care

A Guide to Emerging Clinical Research

  • As modern psychiatry evolves, researchers and clinicians are turning their attention to treatments that challenge traditional models of care. For individuals living with severe or treatment-resistant mental health conditions, ongoing international research has begun to shed light on the potential of substances such as ketamine, psilocybin, and MDMA.
  • These therapies remain tightly regulated in Australia and are only accessible under specific, highly controlled conditions. The following information is provided to promote public understanding and support informed discussion about current mental health research—not to promote or advertise any therapeutic product.

Ketamine in Clinical Psychiatry

Once used almost exclusively as an anaesthetic, ketamine is now being studied in low doses for its effects on mood regulation. Unlike traditional antidepressants, which typically target serotonin, ketamine modulates the brain’s glutamatergic system, potentially promoting rapid shifts in emotional state and neuroplasticity. This overview is provided for general knowledge and reflects current psychiatric research. Treatment decisions remain the responsibility of qualified practitioners.

What Does the Research Say?

Australia and international studies suggest ketamine may help alleviate symptoms of:
  • Major depressive disorder (especially when treatment-resistant)
  • Suicidal ideation
  • Severe anxiety in some clinical contexts
These benefits are typically short-term, and ongoing treatment is approached with caution and professional oversight. Ketamine is not considered a psychedelic under Australian law, and its therapeutic use is distinct from psychedelic-assisted therapy models.

Regulation in Australia

  • Schedule 8 controlled substance
  • Can only be prescribed by registered medical professionals
  • Some formulations (e.g., intranasal esketamine or Spravato®) have TGA approval for treatment-resistant depression
  • Other uses may be considered off-label, within legal and clinical guidelines

Psilocybin – The Future of Emotional Healing?

Psilocybin is a naturally occurring compound found in certain species of mushrooms. It has long been used in spiritual traditions but is now gaining renewed scientific attention for its potential to support psychological recovery in clinical settings—particularly when paired with structured psychotherapeutic support. We share this information in support of public education and to reflect current directions in mental health research. Access is not publicly available without meeting strict regulatory conditions.

Clinical Applications

Studies suggest that psilocybin, when used in a safe, therapeutic environment, may assist individuals with:
  • Treatment-resistant depression
  • Existential distress linked to terminal illness
  • Chronic emotional disengagement
Psilocybin appears to help “reset” entrenched thought patterns and emotional loops, offering a new lens through which individuals can experience their internal world.

Access and Regulation in Australia

  • Schedule 8 controlled substance
  • Can only be prescribed by registered medical professionals
  • Some formulations (e.g., intranasal esketamine or Spravato®) have TGA approval for treatment-resistant depression
  • Other uses may be considered off-label, within legal and clinical guidelines

MDMA – Reimagining Trauma Therapy

MDMA (3,4-methylenedioxymethamphetamine) is being explored globally as a therapeutic adjunct for individuals with severe trauma and PTSD. When used in a controlled therapeutic context, MDMA has been shown to reduce fear responses and increase trust between client and therapist—factors that may be crucial to successful trauma resolution. This information is intended to inform individuals about emerging psychiatric research and is not a substitute for medical advice or a guarantee of treatment availability.

What the Science Shows

Clinical trials, including those led by the Multidisciplinary Association for Psychedelic Studies (MAPS), suggest MDMA-assisted therapy may:
  • Reduce the intensity and frequency of PTSD symptoms
  • Facilitate emotional openness during psychotherapy
  • Support durable improvements in mental health over time

Regulation in Australia

  • Schedule 8 controlled substance (since July 2023)
  • Limited strictly to use for PTSD, and only under the care of TGA-approved psychiatrists
  • Requires ethics committee oversight and controlled clinical protocols

Why Public Education Matters

The field of mental health is evolving, and so is the conversation around how we treat it. We believe that individuals, families, and professionals deserve access to accurate, balanced information about new areas of research—even if those therapies remain restricted or experimental. While ketamine, psilocybin, and MDMA may not be widely accessible, they reflect an important shift in how science is approaching persistent and complex mental health conditions. By offering educational content, we aim to contribute to an informed and respectful national dialogue—one grounded in ethics, evidence, and transparency. This page does not promote the use or availability of any therapeutic substance. It is intended solely for public education, based on published research and current regulatory frameworks.

We're Here for You

Contact us today for a confidential discussion.
contact us
If you are struggling with a mental health crisis or you just need a listening ear, don’t let another day go by. Reach out for help today. Mind Medicine takes appointments for psychiatric assessments or psychotherapy, so please get in touch.
Mind Medicine Pty Ltd Shop 2, 1 Newspaper Place Maroochydore QLD 4558 Tel: +61 7 3040 8208 Fax: 02 5619 2021 ABN: 92 625 381 302
NAVIGATION
CONTACT INFO
+61 7 3040 8208
mymindmedicine.com.au
Please contact us via the contact form to receive the quickest response to your questions and enquiries.
Dr Lana LubimoffRegistered Medical Specialist in Adult, Adolescent, and Child Psychiatry Clinical Psychotherapy and PACFA Accredited SupervisorMBBS FRANZPMedicare Provider No. 569219FJ David MandrakePractice Manager, Mental Health Case Manager and Counsellor Board Certified Hypnotherapist Member of the Australian Counselling Association